Naltrexone
aka - low dose naltrexone
Research
20 / 308 resultsresearch The Opiate Antagonist, Naltrexone, in the Treatment of Trichotillomania
This study found that naltrexone did not significantly reduce hair pulling in adults with trichotillomania compared to placebo, although it improved cognitive flexibility.
research Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris
This case series reported that low-dose naltrexone may benefit patients with lichen planopilaris by reducing scalp symptoms and slowing disease progression, with no adverse effects observed in the patients.
research Trichotillomania Successfully Treated With Risperidone and Naltrexone: A Geriatric Case Report
This review discusses the characteristics, prevalence, and treatment challenges of trichotillomania and provides no new clinical findings.
research Low-Dose Naltrexone: A Novel Adjunctive Treatment in Symptomatic Alopecias?
This article discusses the potential of low-dose naltrexone as an adjuvant therapy for trichodynia in alopecias, noting its anti-inflammatory properties and need for further research.
research Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study
In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.
research Biopharmaceutical Performance of DiluCap: A Line of Functional Excipients Enhancing Dissolution Profiles of Minoxidil, Finasteride, Melatonin, and Naltrexone
In this study, researchers reported that hardshell capsules using the DiluCap® line of excipients demonstrated varying dissolution profiles under gastrointestinal-simulating conditions, with minoxidil and finasteride showing rapid release and melatonin and naltrexone displaying controlled release, indicating their suitability for different applications in compounding pharmacies.
research Efficacy of Oral Naltrexone in the Treatment of Scarring Alopecia
Low-dose oral naltrexone may help reduce inflammation in some scarring alopecia patients.
research Literature Review: Naltrexone: New Use for an Old Drug
This study explores the use of low-dose naltrexone as a novel treatment for lichen planopilaris, but specific results or outcomes are not detailed in the abstract.
research Attenuation of Disease Process Following Treatment with Low-Dose Naltrexone in Patients with Frontal Fibrosing Alopecia and Lichen Planopilaris: A Retrospective Study
Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.
research Reversible Hair Loss in Lichen Planopilaris: Regrowth With Low-Dose Naltrexone and Platelet-Rich Plasma
This case report describes a patient with lichen planopilaris who experienced remarkable hair regrowth at a previously scarred area after treatment with low-dose naltrexone and platelet-rich plasma, following minimal response to other therapies.
research Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment
This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.
research Divergent Neuroactive Steroid Responses to Stress and Ethanol in Rat and Mouse Strains: Relevance for Human Studies
This review discusses the pharmacological properties and physiological regulation of neuroactive steroids, focusing on their varied responses to stress and ethanol in rats, mice, and humans, but it reports no new findings.
research Trichotillomania And Trichophagia: Modern Diagnostic And Therapeutic Methods
This review discusses the diagnostic and treatment challenges of trichotillomania and emphasizes the need for better-designed studies to optimize treatment approaches.
research Recent Advances in the Treatment of Trichotillomania (Hair-Pulling Disorder)
This review discusses recent advances in the pharmacological treatment of trichotillomania, highlighting potential benefits of glutamate-modulating agents, and reports no new clinical results.
research Metabolic Syndrome – A New Definition and Management Guidelines: A Joint Position Paper by Various Polish Medical Societies
This publication discusses the 2021 ESC Guidelines for the prevention of cardiovascular disease in clinical practice and reports no new results.
research Under-Diagnosed Psychiatric Syndrome: Trichotillomania
This review discusses trichotillomania, its prevalence, and treatment options, emphasizing that many sufferers experience delays in treatment due to secrecy and shame, but reports no new research findings.
research Lichen Planopilaris and Frontal Fibrosing Alopecia: Review and Update of Diagnostic and Therapeutic Features
This comprehensive literature review highlighted that lichen planopilaris and frontal fibrosing alopecia, both primary scarring alopecias, are diagnosed via scalp biopsy, with no standardized treatments available, necessitating individualized therapeutic approaches based on patient characteristics.
research Reply
The document concludes that doctors should monitor children's brain development when treating hemangiomas with interferon alfa and consider stopping the treatment if problems arise, while also exploring drugs that might counteract side effects.
research Pharmacy Sanches - Leiria and Pharmaceutical Services at Lusíadas Hospital - Porto
This report details a six-month pharmacy internship in Portugal, where the author engaged in hospital and community pharmacy settings, and discusses scientific topics including obesity medication risks and alopecia treatment options. Results and conclusions are not explicitly reported.
research Update on the Treatment of Trichotillomania
This review outlines current treatment strategies for trichotillomania, noting that while cognitive-behavioral therapy is effective, N-acetylcysteine and memantine are also recommended due to their safety and efficacy, though evidence for other drugs like fluoxetine and naltrexone remains limited.